Sterile tissue
OptiGraft® sterile allografts
Terminally sterilised cornea, sclera and lenticules for glaucoma and corneal surgery, ready to use from the shelf. From Lions World Vision Institute, supplied in South Africa by Evolution Vision.
Overview
What OptiGraft sterile tissue is
OptiGraft sterile tissue is donor cornea and sclera, plus Bowman’s layer and Dua’s layer lenticules, terminally sterilised by electron beam. It is ready to use, with no rinsing or rehydration.
The corneas are clear, which gives the surgeon more placement options.
Uses
What surgeons use it for
Lions World Vision Institute publish OptiGraft sterile tissue for the following uses.
Glaucoma surgery
Tube shunt and valve coverage. Trabeculectomy support. Restoring structural integrity. Bleb, scleral buckle and corneoscleral fistula repair.
Corneal surgery and repair
Corneal perforation. Corneoscleral laceration repair. Tectonic anterior lamellar keratoplasty, ALK and DALK. Boston keratoprosthesis.
Trauma and emergency
Cases that cannot wait for tissue to arrive. Kept at room temperature and ready to use, it goes from the shelf straight into theatre.
Specification
Tissue options
Tissue
Configuration
Size
Cornea
Whole moon, full thickness with scleral rim
Cornea
Whole moon, split thickness
9 mm
Cornea
Half moon, split thickness
9 mm x 4.5 mm
Sclera
10 mm disk
Sclera
Quarter sclera
Anatomical
Sclera
Third sclera
Anatomical
Bowman’s layer lenticule
Anterior cornea
40-70 µm x 9 mm
Dua’s layer lenticule
15-20 µm x 9 mm
Storage
Storage and handling
OptiGraft sterile tissue keeps for up to two years at room temperature.
Corneas are supplied in albumin and sclera in saline, ready to use.
Terminally sterilised by electron beam.
We confirm dating on the tissue offered at the time of enquiry.
Also from Lions World
BrightMEM
Lions World Vision Institute describe BrightMEM as a corneal allograft that promotes regeneration of the corneal epithelium. It is made from Descemet’s membrane, which creates a new foundation for the ocular surface, capable of supporting native limbal epithelial stem cells. They present it as a new treatment for patients with impaired corneal healing and severe corneal disorders, through its regenerative properties.
BrightMEM is aseptically processed rather than terminally sterilised.